Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Biliary Tract Diseases

  Free Subscription

Articles published in Hepatology

Retrieve available abstracts of 199 articles:
HTML format

Single Articles

    August 2022
  1. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    PubMed     Abstract available

  2. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    PubMed     Abstract available

    July 2022
  3. HEUCKE N, Keitel V
    COVID-19-associated cholangiopathy: What's left after the virus has gone?
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32668.

  4. HARTL L, Reiberger T, Trauner M
    On the development of secondary sclerosing cholangitis in chronic liver disease patients after COVID-19.
    Hepatology. 2022 Jul 12. doi: 10.1002/hep.32664.

    June 2022
  5. DENG M, Ran P, Chen L, Wang Y, et al
    Proteogenomic Characterization of Cholangiocarcinoma.
    Hepatology. 2022 Jun 18. doi: 10.1002/hep.32624.
    PubMed     Abstract available

  6. Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32595.
    PubMed     Abstract available

  7. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    PubMed     Abstract available

    May 2022
  8. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    PubMed     Abstract available

  9. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    PubMed     Abstract available

    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.

  11. ZHOU J, Sun Y, Zhang W, Yuan J, et al
    Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32548.
    PubMed     Abstract available

    April 2022
  12. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32543.

  13. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Response to Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32541.

  14. SHCHEYNIKOV N, Boggs K, Green A, Feranchak AP, et al
    Identification of the Chloride Channel, Leucine-Rich Repeat-Containing Protein 8, subfamily A (LRRC8A), in Mouse Cholangiocytes.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32536.
    PubMed     Abstract available

  15. MOHAMAD ZAKI NH, Shiota J, Calder AN, Keeley TM, et al
    C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32492.
    PubMed     Abstract available

  16. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.

    March 2022
  17. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Bile multi-omics analysis classifies lipid species and microbial peptides predictive of Carcinoma of Gall bladder.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32496.
    PubMed     Abstract available

    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.

  19. HENGSTLER JG, Oude Elferink R, van de Graaf SF, Drasdo D, et al
    The de-micellization hypothesis of water influx into bile ducts.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32485.

  20. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    PubMed     Abstract available

  21. BASS LM, Ye W, Hawthorne K, Leung DH, et al
    The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
    PubMed     Abstract available

  22. Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
    Hepatology. 2022;75:773.

  23. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    PubMed     Abstract available

    February 2022
  24. WU MJ, Shi L, Merritt J, Zhu AX, et al
    Biology of IDH Mutant Cholangiocarcinoma.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32424.
    PubMed     Abstract available

  25. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    PubMed     Abstract available

  26. CHAUDHRY HUR, Hayat A, Ahmad A
    Letter to the Editor: Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32416.

  27. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    PubMed     Abstract available

  28. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    PubMed     Abstract available

  29. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available

    January 2022
  30. RUIZ DE GAUNA M, Biancaniello F, Gonzalez-Romero F, Rodrigues PM, et al
    Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32344.
    PubMed     Abstract available

    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.

  32. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    PubMed     Abstract available

  33. Retracted: Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32246.

    December 2021
    Reply to the review <>.
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32296.

  35. VARTAK N, Hengstler JG
    REPLY TO HEP-21-2202: Analysis and limits of detection of biliary flux.
    Hepatology. 2021 Dec 25. doi: 10.1002/hep.32297.

  36. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    PubMed     Abstract available

  37. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    PubMed     Abstract available

  38. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    PubMed     Abstract available

    November 2021
  39. RUBINO JG, Flemming JA
    Menopausal hormone therapy and risk of biliary tract cancers: addressing the ant, not the elephant in the room.
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32254.
    PubMed     Abstract available

  40. JACKSON SS, Pfeiffer RM, Gabbi C, Anderson L, et al
    Menopausal hormone therapy and risk of biliary tract cancers.
    Hepatology. 2021 Nov 11. doi: 10.1002/hep.32198.
    PubMed     Abstract available

  41. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    PubMed     Abstract available

  42. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    PubMed     Abstract available

  43. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    PubMed     Abstract available

    October 2021
  44. ZIMMER CL, Filipovic I, Cornillet M, O'Rourke CJ, et al
    MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32222.
    PubMed     Abstract available

  45. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed     Abstract available

  46. LINDOR KD, Dawson PA, Trauner M
    Alan Hofmann (1931-2021): A Career Well Spent Understanding Bile Acids.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32206.
    PubMed     Abstract available

  47. FAIRFIELD CJ, Drake TM, Pius R, Bretherick AD, et al
    Genome-wide Analysis Identifies Novel Gallstone-susceptibility Loci Including Genes Regulating Gastrointestinal Motility.
    Hepatology. 2021 Oct 15. doi: 10.1002/hep.32199.
    PubMed     Abstract available

  48. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    PubMed     Abstract available

  49. CHEN L, Yang H, Li H, He C, et al
    Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.
    Hepatology. 2021 Oct 8. doi: 10.1002/hep.32183.
    PubMed     Abstract available

  50. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.

  51. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    PubMed     Abstract available

    September 2021
  52. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    PubMed     Abstract available

  53. HUNG HY, Wang CC, Wei JC
    Letter to the Editor: Postdiagnosis aspirin use associated with decreased biliary tract cancer?
    Hepatology. 2021 Sep 23. doi: 10.1002/hep.32170.
    PubMed     Abstract available

  54. VARTAK N, Hengstler JG
    Response to 21-1766: Challenging the dogma of canalicular bile flow.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32168.
    PubMed     Abstract available

  55. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    PubMed     Abstract available

  56. JAVITT NB, Boyer JL
    Letter to the Editor: On the Mechanisms of Biliary Flux.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32167.
    PubMed     Abstract available

  57. DE JONG IEM, Overi D, Carpino G, Gouw ASH, et al
    Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32166.
    PubMed     Abstract available

  58. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    PubMed     Abstract available

  59. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    PubMed     Abstract available

  60. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    PubMed     Abstract available

  61. WANG Y, Hylemon PB, Zhou H
    Long Noncoding RNA H19: A Key Player in Liver Diseases.
    Hepatology. 2021;74:1652-1659.

    August 2021
  62. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
    Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
    PubMed     Abstract available

  63. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    PubMed     Abstract available

  64. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
    Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
    Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
    PubMed     Abstract available

  65. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
    Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
    PubMed     Abstract available

  66. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    PubMed     Abstract available

  67. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    PubMed     Abstract available

  68. ZENG R, Sha W, Leung FW, Chen H, et al
    Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
    PubMed     Abstract available

    July 2021
  69. PANT K, Peixoto E, Richard S, Biswas A, et al
    Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
    PubMed     Abstract available

  70. CAI P, Mao X, Zhao J, Nie L, et al
    Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
    PubMed     Abstract available

  71. WADHWANI SI, Gottlieb L, Bucuvalas JC, Lyles C, et al
    Addressing social adversity to improve outcomes for children after liver transplant.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32073.
    PubMed     Abstract available

  72. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
    NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
    PubMed     Abstract available

  73. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
    ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
    Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
    PubMed     Abstract available

  74. ZHANG JW, Yang X, Ding HR, Zhang L, et al
    Is aspirin a drug or just a marker for biliary cancer?
    Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
    PubMed     Abstract available

  75. LEE MH, Huang YH, Koshiol J
    Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
    Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
    PubMed     Abstract available

  76. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
    Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
    PubMed     Abstract available

  77. WANG H, Song X, Liao H, Wang P, et al
    Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Hepatology. 2021;74:248-263.
    PubMed     Abstract available

    June 2021
  78. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
    On the mechanisms of biliary flux.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
    PubMed     Abstract available

  79. SHI S, Chen S, Verstegen MMA, Pan Q, et al
    Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
    PubMed     Abstract available

  80. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
    Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
    PubMed     Abstract available

  81. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    PubMed     Abstract available

  82. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    PubMed     Abstract available

  83. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    PubMed     Abstract available

    May 2021
  84. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    PubMed     Abstract available

  85. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available

  86. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available

  87. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
    Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
    Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
    PubMed     Abstract available

  88. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    PubMed     Abstract available

  89. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    PubMed     Abstract available

  90. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    PubMed     Abstract available

  91. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
    Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
    PubMed     Abstract available

  92. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
    Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
    PubMed     Abstract available

  93. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
    Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
    PubMed     Abstract available

    April 2021
  94. YOON JG, Kim MH, Jang M, Kim H, et al
    Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
    Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
    PubMed     Abstract available

  95. XU Y, Leng K, Yao Y, Kang P, et al
    A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
    Hepatology. 2021;73:1419-1435.
    PubMed     Abstract available

  96. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    PubMed     Abstract available

    March 2021
  97. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    PubMed     Abstract available

  98. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    PubMed     Abstract available

  99. LUO X, Campbell NA, He L, O'Brien DR, et al
    SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
    PubMed     Abstract available

  100. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    PubMed     Abstract available

  101. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    PubMed     Abstract available

  102. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    PubMed     Abstract available

  103. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    PubMed     Abstract available

  104. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    PubMed     Abstract available

    February 2021
  105. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    PubMed     Abstract available

  106. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
    Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
    PubMed     Abstract available

  107. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    PubMed     Abstract available

  108. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available

  109. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    PubMed     Abstract available

  110. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    PubMed     Abstract available

  111. JAVITT NB
    Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
    PubMed     Abstract available

  112. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    PubMed     Abstract available

  113. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    PubMed     Abstract available

  114. NASSER-GHODSI N, Mara K, Watt KD
    De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
    PubMed     Abstract available

    January 2021
  115. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    PubMed     Abstract available

  116. LI J, Ye X, He S
    Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
    Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
    PubMed     Abstract available

  117. ASSIS DN, Levy C
    Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
    Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
    PubMed     Abstract available

  118. FENG GS, Hanley KL, Liang Y, Lin X, et al
    Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Hepatology. 2021;73 Suppl 1:104-114.
    PubMed     Abstract available

  119. RIZVI S, Wang J, El-Khoueiry AB
    Liver Cancer Immunity.
    Hepatology. 2021;73 Suppl 1:86-103.

  120. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
    Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Hepatology. 2021;73 Suppl 1:49-61.
    PubMed     Abstract available

    December 2020
  121. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    PubMed     Abstract available

    November 2020
  122. KNOOIHUIZEN SAI, Aday A, Lee WM
    Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
    PubMed     Abstract available

  123. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    PubMed     Abstract available

  124. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
    Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
    PubMed     Abstract available

  125. SATO K, Zhang W, Safarikia S, Isidan A, et al
    Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
    PubMed     Abstract available

  126. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
    Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
    PubMed     Abstract available

  127. MEADOWS V, Francis H
    DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
    PubMed     Abstract available

  128. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    PubMed     Abstract available

    October 2020
  129. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    PubMed     Abstract available

  130. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    PubMed     Abstract available

  131. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
    Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
    PubMed     Abstract available

  132. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available

    September 2020
  133. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
    DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
    PubMed     Abstract available

  134. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
    Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
    PubMed     Abstract available

  135. CHEN D, Wu H, Feng X, Chen Y, et al
    DNA Methylation of CNRIP1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent PKM2 Ubiquitination.
    Hepatology. 2020 Sep 21. doi: 10.1002/hep.31561.
    PubMed     Abstract available

  136. DENEAU MR
    Oral vancomycin, ursodeoxycholic acid or no therapy for pediatric primary sclerosing cholangitis: a matched analysis.
    Hepatology. 2020 Sep 18. doi: 10.1002/hep.31560.
    PubMed     Abstract available

  137. CHEN L, Zhou T, White T, O'Brien A, et al
    The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
    PubMed     Abstract available

  138. BARAHONA PONCE C, Scherer D, Brinster R, Boekstegers F, et al
    Gallstones, Body Mass Index, C-reactive Protein and Gallbladder Cancer - Mendelian Randomization Analysis of Chilean and European Genotype Data.
    Hepatology. 2020 Sep 6. doi: 10.1002/hep.31537.
    PubMed     Abstract available

    August 2020
  139. MERDRIGNAC A, Papoutsoglou P, Coulouarn C
    Long non-coding RNAs in cholangiocarcinoma.
    Hepatology. 2020 Aug 31. doi: 10.1002/hep.31534.
    PubMed     Abstract available

  140. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available

  141. LUO Y, Brigham D, Bednarek J, Torres R, et al
    Unique cholangiocyte-targeted IgM autoantibodies correlate with poor outcome in biliary atresia.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31504.
    PubMed     Abstract available

  142. FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
    Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
    Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
    PubMed     Abstract available

  143. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available

  144. BAI X, Zhang H, Zhou Y, Nagaoka K, et al
    TET1 promotes malignant progression of cholangiocarcinoma with IDH1 wild-type.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31486.
    PubMed     Abstract available

  145. WU N, Baiocchi L, Zhou T, Kennedy L, et al
    The Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31484.
    PubMed     Abstract available

    July 2020
  146. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
    Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
    Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
    PubMed     Abstract available

  147. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
    Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
    PubMed     Abstract available

  148. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    PubMed     Abstract available

  149. XIAO Y, Chen Q, Xu G, Mao Y, et al
    Letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
    Hepatology. 2020 Jul 20. doi: 10.1002/hep.31470.
    PubMed     Abstract available

  150. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.

    June 2020
  151. VAN IJZENDOORN SCD, Li Q, Qiu YL, Wang JS, et al
    Unequal effects of MYO5B mutations in liver and intestine determine the clinical presentation of low-GGT cholestasis.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31430.
    PubMed     Abstract available

  152. VARTAK N, Guenther G, Joly F, Damle-Vartak A, et al
    Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2020 Jun 19. doi: 10.1002/hep.31422.
    PubMed     Abstract available

  153. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    PubMed     Abstract available

  154. FABRIS L, Sato K, Alpini G, Strazzabosco M, et al
    The Tumor Microenvironment in Cholangiocarcinoma Progression.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31410.
    PubMed     Abstract available

    May 2020
  155. DENEAU MR, Mack C, Perito ER, Ricciuto A, et al
    The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children.
    Hepatology. 2020 May 28. doi: 10.1002/hep.31393.
    PubMed     Abstract available

  156. YAN C, Koda S, Wu J, Zhang BB, et al
    Roles of trained immunity in the pathogenesis of cholangiopathies: a novel therapeutic target.
    Hepatology. 2020 May 28. doi: 10.1002/hep.31395.
    PubMed     Abstract available

  157. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    PubMed     Abstract available

  158. DEAN G, Hanauer S, Levitsky J
    The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications.
    Hepatology. 2020 May 11. doi: 10.1002/hep.31311.
    PubMed     Abstract available

  159. ZHANG Y, Wang H, Chen T, Wang H, et al
    C24 -Ceramide Drives Gallbladder Cancer Progression through Directly Targeting PIP4K2C to Facilitate mTOR Signaling Activation.
    Hepatology. 2020 May 6. doi: 10.1002/hep.31304.
    PubMed     Abstract available

  160. JAVITT NB
    Blocking Sodum-Taurocholate Cotransporting Polypeptide Stimulates Biliary Cholesterol and Phospholipid Secretion in Mice.
    Hepatology. 2020 May 4. doi: 10.1002/hep.31292.
    PubMed     Abstract available

    April 2020
  161. CHEN J, Vitetta L
    Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31269.
    PubMed     Abstract available

  162. O'ROURKE CJ, Munoz-Garrido P, Andersen JB
    Molecular targets in cholangiocarcinoma.
    Hepatology. 2020 Apr 18. doi: 10.1002/hep.31278.
    PubMed     Abstract available

  163. TRAUNER M, Chung C, Myers RP, Kowdley KV, et al
    Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Hepatology. 2020 Apr 12. doi: 10.1002/hep.31268.
    PubMed     Abstract available

  164. LARGHI A, Rimbas M, Ardito F, Rizzatti G, et al
    EUS-FNA for lymph nodes staging in cholangiocarcinoma: should it become standard of care?
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31266.
    PubMed     Abstract available

  165. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    PubMed     Abstract available

    March 2020
  166. RIMLAND CA, Tilson SG, Morell CM, Tomaz RA, et al
    Regional differences in human biliary tissues and corresponding in vitro derived organoids.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31252.
    PubMed     Abstract available

  167. VATS R, Liu S, Zhu J, Mukhi D, et al
    Impaired bile secretion promotes hepatobiliary injury in Sickle Cell Disease.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31239.
    PubMed     Abstract available

  168. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    PubMed     Abstract available

  169. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available

  170. LAVU S, Therneau TM, Harmsen WS, Mara KC, et al
    Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma.
    Hepatology. 2020 Mar 2. doi: 10.1002/hep.31146.
    PubMed     Abstract available

  171. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    PubMed     Abstract available

    February 2020
  172. WANG HH, de Bari O, Arnatt CK, Liu M, et al
    Activation of a novel estrogen receptor GPR30 enhances cholesterol cholelithogenesis in female mice.
    Hepatology. 2020 Feb 29. doi: 10.1002/hep.31212.
    PubMed     Abstract available

  173. ZHU Y, Kwong LN
    Insights into the origin of intrahepatic cholangiocarcinoma from mouse models.
    Hepatology. 2020 Feb 24. doi: 10.1002/hep.31200.
    PubMed     Abstract available

  174. CHATURANTABUT S, Shwartz A, Garnaas MK, LaBella K, et al
    Estrogen acts via estrogen receptor 2b to regulate hepatobiliary fate during vertebrate development.
    Hepatology. 2020 Feb 14. doi: 10.1002/hep.31184.
    PubMed     Abstract available

  175. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    PubMed     Abstract available

    January 2020
  176. MA W, Han C, Zhang J, Song K, et al
    The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
    Hepatology. 2020 Jan 28. doi: 10.1002/hep.31141.
    PubMed     Abstract available

  177. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC).
    Hepatology. 2020 Jan 23. doi: 10.1002/hep.31140.
    PubMed     Abstract available

  178. GOEPPERT B, Folseraas T, Roessler S, Kloor M, et al
    Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities.
    Hepatology. 2020 Jan 10. doi: 10.1002/hep.31110.
    PubMed     Abstract available

  179. LIN A, Alpert L, Hart J, Chapman C, et al
    Lymphoepithelioma-like carcinomas - a rare variant of cholangiocarcinoma.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31102.
    PubMed     Abstract available

  180. GOODE EC, Hirschfield GM, Rushbrook SM
    Hepatology. 2020;71:399-400.

  181. WANG J, Geskus RB, Leeflang MMG, Ponsioen CY, et al
    Letter to the Editor: Fair Comparisons in the Arena of Risk Scores.
    Hepatology. 2020;71:398-399.

    December 2019
  182. CAROTENUTO P, Hedayat S, Fassan M, Cardinale V, et al
    Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells.
    Hepatology. 2019 Dec 26. doi: 10.1002/hep.31094.
    PubMed     Abstract available

  183. JOB S, Rapoud D, Dos Santos A, Gonzalez P, et al
    Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Dec 25. doi: 10.1002/hep.31092.
    PubMed     Abstract available

  184. STUART L, Lambourne B, Turner P, Jones DE, et al
    HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
    PubMed     Abstract available

  185. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available

  186. LOZANO E, Asensio M, Perez-Silva L, Banales JM, et al
    MRP3-mediated chemoresistance in cholangiocarcinoma: Target for chemosensitization through restoring SOX17 expression.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31088.
    PubMed     Abstract available

  187. MALIKOWSKI T, Levy MJ, Gleeson FC, Storm AC, et al
    EUS-FNA is effective for lymph node staging in patients with cholangiocarcinoma.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31077.
    PubMed     Abstract available

  188. SHUNG DL, Assis DN
    Machine Learning in a Complex Disease: PREsTo Improves The Prognostication of Primary Sclerosing Cholangitis.
    Hepatology. 2019 Dec 18. doi: 10.1002/hep.31069.
    PubMed     Abstract available

  189. GUICCIARDI ME, Trussoni CE, LaRusso NF, Gores GJ, et al
    The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis.
    Hepatology. 2019 Dec 13. doi: 10.1002/hep.31067.
    PubMed     Abstract available

    November 2019
  190. OVEREEM AW, Li Q, Qiu YL, Carton-Garcia F, et al
    A molecular mechanism underlying genotype-specific intrahepatic cholestasis resulting from MYO5B mutations.
    Hepatology. 2019 Nov 21. doi: 10.1002/hep.31002.
    PubMed     Abstract available

  191. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available

    October 2019
  192. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    PubMed     Abstract available

    September 2019
  193. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available

  194. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available

  195. WAN ZH, Jiang TY, Shi YY, Pan YF, et al
    RPB5-mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding.
    Hepatology. 2019 Sep 21. doi: 10.1002/hep.30962.
    PubMed     Abstract available

  196. KIM HB, Elisofon SA
    Hepatology Elsewhere.
    Hepatology. 2019 Sep 13. doi: 10.1002/hep.30935.
    PubMed     Abstract available

    February 2019
  197. WEN W, Schwabe RF
    Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma.
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30565.
    PubMed     Abstract available

    January 2019
  198. PRATT DS
    Hepatology Elsewhere.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30517.
    PubMed     Abstract available

    December 2018
  199. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.